Company Profile
Pharmicell Co., Ltd., a biopharmaceutical company develops and sells autologous drugs in South Korea and globally. The company operates in Biopharmaceutical Business and Biochemical Business divisions.
It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty.
The company's products under development include Cellgram_LC to treat hepatic insufficiency. Its portfolio also includes Cellgram_ED for treating impotence, and Hearticellgram_AMI, a cardiac disease drug.
It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc Half-Serum DMEM, a cell culture medium; and PharmiSTEM culture medium for mesenchymal stem cells, as well as clinical development and commercialization services for new drugs.
It also operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. Founded in 1968 and headquartered in Seoul, South Korea, Pharmicell was formerly known as FcB2welve Co., Ltd before rebranding in September 2011.